|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ALG1 |
Gene summary for ALG1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ALG1 | Gene ID | 56052 |
| Gene name | ALG1 chitobiosyldiphosphodolichol beta-mannosyltransferase | |
| Gene Alias | CDG1K | |
| Cytomap | 16p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q9BT22 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 56052 | ALG1 | LZE4T | Human | Esophagus | ESCC | 5.33e-13 | 2.07e-01 | 0.0811 |
| 56052 | ALG1 | LZE8T | Human | Esophagus | ESCC | 2.63e-03 | 7.52e-02 | 0.067 |
| 56052 | ALG1 | LZE20T | Human | Esophagus | ESCC | 7.82e-04 | 1.30e-01 | 0.0662 |
| 56052 | ALG1 | LZE22D1 | Human | Esophagus | HGIN | 2.92e-02 | 1.47e-01 | 0.0595 |
| 56052 | ALG1 | LZE22T | Human | Esophagus | ESCC | 2.96e-03 | 2.74e-01 | 0.068 |
| 56052 | ALG1 | LZE24T | Human | Esophagus | ESCC | 1.66e-10 | 3.14e-01 | 0.0596 |
| 56052 | ALG1 | P1T-E | Human | Esophagus | ESCC | 4.14e-06 | 1.69e-01 | 0.0875 |
| 56052 | ALG1 | P2T-E | Human | Esophagus | ESCC | 7.82e-27 | 5.16e-01 | 0.1177 |
| 56052 | ALG1 | P4T-E | Human | Esophagus | ESCC | 1.36e-10 | 2.39e-01 | 0.1323 |
| 56052 | ALG1 | P5T-E | Human | Esophagus | ESCC | 1.43e-13 | 2.21e-01 | 0.1327 |
| 56052 | ALG1 | P8T-E | Human | Esophagus | ESCC | 1.19e-15 | 2.41e-01 | 0.0889 |
| 56052 | ALG1 | P9T-E | Human | Esophagus | ESCC | 4.89e-09 | 8.05e-02 | 0.1131 |
| 56052 | ALG1 | P10T-E | Human | Esophagus | ESCC | 5.49e-14 | 1.27e-01 | 0.116 |
| 56052 | ALG1 | P11T-E | Human | Esophagus | ESCC | 3.17e-05 | 2.60e-01 | 0.1426 |
| 56052 | ALG1 | P12T-E | Human | Esophagus | ESCC | 2.86e-31 | 4.03e-01 | 0.1122 |
| 56052 | ALG1 | P15T-E | Human | Esophagus | ESCC | 8.17e-18 | 3.27e-01 | 0.1149 |
| 56052 | ALG1 | P16T-E | Human | Esophagus | ESCC | 3.41e-20 | 2.10e-01 | 0.1153 |
| 56052 | ALG1 | P17T-E | Human | Esophagus | ESCC | 1.30e-10 | 3.38e-01 | 0.1278 |
| 56052 | ALG1 | P19T-E | Human | Esophagus | ESCC | 2.08e-04 | 2.16e-01 | 0.1662 |
| 56052 | ALG1 | P20T-E | Human | Esophagus | ESCC | 1.12e-16 | 2.62e-01 | 0.1124 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00064876 | Esophagus | HGIN | protein N-linked glycosylation | 17/2587 | 65/18723 | 6.04e-03 | 4.87e-02 | 17 |
| GO:0006457110 | Esophagus | ESCC | protein folding | 163/8552 | 212/18723 | 1.13e-20 | 1.74e-18 | 163 |
| GO:000648714 | Esophagus | ESCC | protein N-linked glycosylation | 51/8552 | 65/18723 | 6.41e-08 | 1.13e-06 | 51 |
| GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
| GO:00700854 | Esophagus | ESCC | glycosylation | 144/8552 | 240/18723 | 5.12e-06 | 5.38e-05 | 144 |
| GO:00064865 | Esophagus | ESCC | protein glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00434135 | Esophagus | ESCC | macromolecule glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00091012 | Esophagus | ESCC | glycoprotein biosynthetic process | 181/8552 | 317/18723 | 2.54e-05 | 2.15e-04 | 181 |
| GO:00064882 | Esophagus | ESCC | dolichol-linked oligosaccharide biosynthetic process | 14/8552 | 18/18723 | 5.77e-03 | 2.14e-02 | 14 |
| GO:00064902 | Esophagus | ESCC | oligosaccharide-lipid intermediate biosynthetic process | 14/8552 | 19/18723 | 1.27e-02 | 4.21e-02 | 14 |
| GO:00064577 | Liver | Cirrhotic | protein folding | 114/4634 | 212/18723 | 9.23e-20 | 2.31e-17 | 114 |
| GO:00064873 | Liver | Cirrhotic | protein N-linked glycosylation | 30/4634 | 65/18723 | 1.40e-04 | 1.36e-03 | 30 |
| GO:000645712 | Liver | HCC | protein folding | 160/7958 | 212/18723 | 1.07e-22 | 1.88e-20 | 160 |
| GO:000648711 | Liver | HCC | protein N-linked glycosylation | 48/7958 | 65/18723 | 2.85e-07 | 5.00e-06 | 48 |
| GO:00064862 | Liver | HCC | protein glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
| GO:00434132 | Liver | HCC | macromolecule glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
| GO:00700852 | Liver | HCC | glycosylation | 128/7958 | 240/18723 | 4.35e-04 | 2.92e-03 | 128 |
| GO:0009100 | Liver | HCC | glycoprotein metabolic process | 193/7958 | 387/18723 | 1.89e-03 | 9.62e-03 | 193 |
| GO:000645718 | Oral cavity | OSCC | protein folding | 154/7305 | 212/18723 | 1.89e-23 | 4.60e-21 | 154 |
| GO:00064875 | Oral cavity | OSCC | protein N-linked glycosylation | 44/7305 | 65/18723 | 2.63e-06 | 3.26e-05 | 44 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa005106 | Esophagus | HGIN | N-Glycan biosynthesis | 17/1383 | 53/8465 | 3.43e-03 | 2.54e-02 | 2.02e-02 | 17 |
| hsa0051013 | Esophagus | HGIN | N-Glycan biosynthesis | 17/1383 | 53/8465 | 3.43e-03 | 2.54e-02 | 2.02e-02 | 17 |
| hsa0051023 | Esophagus | ESCC | N-Glycan biosynthesis | 39/4205 | 53/8465 | 3.26e-04 | 1.15e-03 | 5.89e-04 | 39 |
| hsa005136 | Esophagus | ESCC | Various types of N-glycan biosynthesis | 31/4205 | 42/8465 | 1.23e-03 | 3.78e-03 | 1.93e-03 | 31 |
| hsa0051033 | Esophagus | ESCC | N-Glycan biosynthesis | 39/4205 | 53/8465 | 3.26e-04 | 1.15e-03 | 5.89e-04 | 39 |
| hsa0051313 | Esophagus | ESCC | Various types of N-glycan biosynthesis | 31/4205 | 42/8465 | 1.23e-03 | 3.78e-03 | 1.93e-03 | 31 |
| hsa0051021 | Liver | HCC | N-Glycan biosynthesis | 40/4020 | 53/8465 | 2.95e-05 | 1.87e-04 | 1.04e-04 | 40 |
| hsa005132 | Liver | HCC | Various types of N-glycan biosynthesis | 30/4020 | 42/8465 | 1.41e-03 | 5.07e-03 | 2.82e-03 | 30 |
| hsa0051031 | Liver | HCC | N-Glycan biosynthesis | 40/4020 | 53/8465 | 2.95e-05 | 1.87e-04 | 1.04e-04 | 40 |
| hsa005133 | Liver | HCC | Various types of N-glycan biosynthesis | 30/4020 | 42/8465 | 1.41e-03 | 5.07e-03 | 2.82e-03 | 30 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ALG1 | SNV | Missense_Mutation | c.252N>T | p.Gln84His | p.Q84H | Q9BT22 | protein_coding | tolerated(0.27) | benign(0) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ALG1 | SNV | Missense_Mutation | novel | c.276G>T | p.Gln92His | p.Q92H | Q9BT22 | protein_coding | deleterious(0.04) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ALG1 | SNV | Missense_Mutation | rs150272167 | c.946G>A | p.Val316Ile | p.V316I | Q9BT22 | protein_coding | tolerated(0.36) | benign(0.144) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ALG1 | SNV | Missense_Mutation | c.1387G>A | p.Asp463Asn | p.D463N | Q9BT22 | protein_coding | tolerated(0.16) | benign(0.115) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| ALG1 | SNV | Missense_Mutation | c.485N>A | p.Ser162Tyr | p.S162Y | Q9BT22 | protein_coding | deleterious(0) | possibly_damaging(0.885) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ALG1 | SNV | Missense_Mutation | rs145317306 | c.787C>T | p.Arg263Trp | p.R263W | Q9BT22 | protein_coding | tolerated(0.19) | benign(0.005) | TCGA-VS-A8EB-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | PD |
| ALG1 | SNV | Missense_Mutation | c.481N>C | p.Tyr161His | p.Y161H | Q9BT22 | protein_coding | tolerated(0.15) | probably_damaging(0.994) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ALG1 | SNV | Missense_Mutation | c.806N>C | p.Leu269Pro | p.L269P | Q9BT22 | protein_coding | tolerated(0.25) | benign(0.124) | TCGA-AY-6197-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| ALG1 | SNV | Missense_Mutation | rs143906919 | c.764N>T | p.Thr255Met | p.T255M | Q9BT22 | protein_coding | tolerated(0.27) | benign(0.005) | TCGA-QG-A5Z2-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| ALG1 | deletion | Frame_Shift_Del | c.398delC | p.Pro133GlnfsTer59 | p.P133Qfs*59 | Q9BT22 | protein_coding | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |